EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review

Isao Murakami iD, Hiroko Machida iD, Tohru Morisada iD, Yasuhisa Terao iD, Tsutomu Tabata iD, Mikio Mikami iD, Yasuyuki Hirashima iD, Yoichi Kobayashi iD, Tsukasa Baba iD, Satoru Nagase iD

Journal of Gynecologic Oncology · 2023

DOI: 10.3802/jgo.2023.34.e49 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Gynecologic Oncology, 2023. Verfasst von Isao Murakami und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Toho University Ohashi Medical Center, Tokyo, Japan. isao.murakami@med.toho-u.ac.jp. Hauptthemen laut MEDLINE: Endometrial Hyperplasia, Endometrial Neoplasms, Fertility Preservation. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To examine the effectiveness of progestin re-treatment for recurrent endometrial intraepithelial neoplasia (EIN), atypical endometrial hyperplasia (AH) and endometrial cancer (EC) following initial fertility-sparing treatment. METHODS: A comprehensive systematic review and meta-analysis were conducted by an Expert Panel of the Japan Society of Gynecologic Oncology Endometrial Cancer Committee. Multiple search engines, including PubMed/MEDLINE and the Cochrane Database, were searched in December 2021 using the keywords "Endometrial neoplasms," "Endometrial hyperplasia," "Endometrial intraepithelial neoplasia," "Fertility preservation," "Progestins," AND "Recurrence." Cases describing progestin re-treatment for recurrent EIN, AH and EC were compared with cases that underwent conventional hysterectomy. The primary outcomes were survival and disease recurrence, and the secondary outcome was pregnancy. RESULTS: After screening 238 studies, 32 with results for recurrent treatment were identified. These studies included 365 patients (270 received progestin re-treatment and 95 underwent hysterectomy). Most progestin re-treatment involved medroxyprogesterone acetate or megestrol acetate (94.5%). Complete remission (CR) following progestin re-treatment was achieved in 219 (81.1%) cases, with 3-, 6- and 9-month cumulative CR rates of 22.8%, 51.7% and 82.6%, respectively. Progestin re-treatment was associated with higher risk of disease recurrence than conventional hysterectomy was (odds ratio [OR]=6.78; 95% confidence interval [CI]=1.99-23.10), and one patient (0.4%) died of disease. Fifty-one (14.0%) women became pregnant after recurrence, and progestin re-treatment demonstrated a possibility of pregnancy (OR=2.48; 95% CI=0.94-6.58). CONCLUSION: This meta-analysis suggests that repeat progestin therapy is an effective option for women with recurrent EIN, AH and EC, who wish to retain their fertility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial HyperplasiaEndometrial NeoplasmsFertility PreservationPregnancyFemaleHumansProgestinsRetrospective StudiesNeoplasm Recurrence, LocalTreatment Outcome

Stichwörter der Autor:innen

Endometrial HyperplasiaEndometrial NeoplasmFertility PreservationProgestinsRecurrence

Substanzen

Progestins

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Toho University Ohashi Medical Center, Tokyo, Japan. isao.murakami@med.toho-u.ac.jp.
  • Department of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara, Japan.
  • Department of Obstetrics and Gynecology, Kyorin University Faculty of Medicine, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, Tokyo Women's Medical University, Tokyo, Japan.
  • Division of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.

ORCID-Profile: Isao Murakami, Hiroko Machida, Tohru Morisada, Yasuhisa Terao, Tsutomu Tabata, Mikio Mikami, Yasuyuki Hirashima, Yoichi Kobayashi, Tsukasa Baba, Satoru Nagase

Zitieren

APA

Murakami, I., Machida, H., Morisada, T., Terao, Y., Tabata, T., Mikami, M., Hirashima, Y., Kobayashi, Y., Baba, T., & Nagase, S. (2023). Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2023.34.e49

Vancouver

Murakami I, Machida H, Morisada T, Terao Y, Tabata T, Mikami M, et al. Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review. Journal of Gynecologic Oncology. 2023. doi:10.3802/jgo.2023.34.e49

BibTeX
@article{Murakami2023,
  author = {Murakami, Isao and Machida, Hiroko and Morisada, Tohru and Terao, Yasuhisa and Tabata, Tsutomu and Mikami, Mikio and Hirashima, Yasuyuki and Kobayashi, Yoichi and Baba, Tsukasa and Nagase, Satoru},
  title = {Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review},
  journal = {Journal of Gynecologic Oncology},
  year = {2023},
  doi = {10.3802/jgo.2023.34.e49}
}
Kostenlos starten →